infinity pharmaceuticals inc
(INFI:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)
As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for infinity pharmaceuticals inc (INFI)
Year over year, Infinity Pharmaceuticals, Inc. has seen revenues fall from $92.8M USD to $47.1M USD. This along with an increase in SGA costs has led to a reduction in the bottom line from a loss of $40.0M USD to an even larger loss of $54.0M USD.
| Currency in Millions of US Dollars | As of: | Dec 31 2009 Restated | Dec 31 2010 Restated | Dec 31 2011 Restated | Dec 31 2012 | 4 Year Trend |
| Revenues | 50.8 | 71.3 | 92.8 | 47.1 |  | |
| TOTAL REVENUES | 50.8 | 71.3 | 92.8 | 47.1 | | |
| Cost of Goods Sold | 46.5 | 67.0 | 88.5 | 45.0 | | |
| GROSS PROFIT | 4.3 | 4.3 | 4.3 | 2.1 | | |
| Selling General & Admin Expenses, Total | 19.5 | 21.1 | 22.7 | 26.7 | | |
| R&D Expenses | 31.4 | 32.2 | 20.1 | 73.6 | | |
| OTHER OPERATING EXPENSES, TOTAL | 50.8 | 53.3 | 42.8 | 100.3 | | |
| OPERATING INCOME | -46.5 | -49.0 | -38.5 | -98.2 | | |
| Interest Expense | -1.3 | -1.9 | -1.8 | -1.9 | | |
| Interest and Investment Income | 2.0 | 0.5 | 0.3 | 0.6 | | |
| Other Non-Operating Expenses, Total | -- | 0.7 | -- | 0.2 | | |
| Other Non-Operating Income (Expenses) | -- | 0.7 | -- | 0.2 | | |
| Other Unusual Items, Total | 14.2 | -- | -- | 45.4 | | |
| EBT, INCLUDING UNUSUAL ITEMS | -31.6 | -49.7 | -40.0 | -54.0 | | |
| Income Tax Expense | -0.3 | -0.7 | -- | -- | | |
| Earnings from Continuing Operations | -31.3 | -49.0 | -40.0 | -54.0 | | |
| NET INCOME | -31.3 | -49.0 | -40.0 | -54.0 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | -31.3 | -49.0 | -40.0 | -54.0 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | -31.3 | -49.0 | -40.0 | -54.0 | | |
| Recently Viewed | |||
| INFI:US | $24.91 USD | +0.59 |  |
| Company | Last | Change |
| Array BioPharma Inc | $5.89 USD | +0.20 |
| Astex Pharmaceuticals | $5.59 USD | +0.17 |
| Exact Sciences Corp | $10.56 USD | -0.26 |
| Exelixis Inc | $4.55 USD | 0.00 |
| Keryx Biopharmaceuticals Inc | $8.04 USD | +0.04 |
| View Industry Companies | ||
Industry Analysis
INFI
Industry Average
| Valuation | INFI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 52.9x |
|
| Price/Book | 4.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 40.8x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
